- Home
- PRQR vs NAMI Comparison
PRQR vs NAMI Comparison
Compare PRQR & NAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- NAMI
- Stock Information
- Founded
- PRQR 2012
- NAMI 2014
- Country
- PRQR Netherlands
- NAMI China
- Employees
- PRQR 166
- NAMI N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- NAMI
- Sector
- PRQR Health Care
- NAMI
- Exchange
- PRQR Nasdaq
- NAMI NYSE
- Market Cap
- PRQR 244.4M
- NAMI 185.3M
- IPO Year
- PRQR 2014
- NAMI 2024
- Fundamental
- Price
- PRQR $2.26
- NAMI $1.05
- Analyst Decision
- PRQR Strong Buy
- NAMI
- Analyst Count
- PRQR 8
- NAMI 0
- Target Price
- PRQR $8.88
- NAMI N/A
- AVG Volume (30 Days)
- PRQR 342.1K
- NAMI 32.6K
- Earning Date
- PRQR 08-07-2025
- NAMI 08-11-2025
- Dividend Yield
- PRQR N/A
- NAMI N/A
- EPS Growth
- PRQR N/A
- NAMI N/A
- EPS
- PRQR N/A
- NAMI 0.10
- Revenue
- PRQR $21,212,711.00
- NAMI $55,677,960.00
- Revenue This Year
- PRQR N/A
- NAMI N/A
- Revenue Next Year
- PRQR N/A
- NAMI N/A
- P/E Ratio
- PRQR N/A
- NAMI $10.44
- Revenue Growth
- PRQR 85.91
- NAMI 7.00
- 52 Week Low
- PRQR $1.07
- NAMI $0.97
- 52 Week High
- PRQR $4.62
- NAMI $7.75
- Technical
- Relative Strength Index (RSI)
- PRQR 56.82
- NAMI N/A
- Support Level
- PRQR $2.27
- NAMI N/A
- Resistance Level
- PRQR $2.51
- NAMI N/A
- Average True Range (ATR)
- PRQR 0.13
- NAMI 0.00
- MACD
- PRQR -0.00
- NAMI 0.00
- Stochastic Oscillator
- PRQR 51.49
- NAMI 0.00
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The company generates revenue by selling its content to hardware manufacturers in China whereby are allowed to install the company's digital educational content on the manufacturers' devices for sale to end users.